Document Detail

Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid.
MedLine Citation:
PMID:  15812447     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate safety and benefits of feeding preterm infants formulas containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) until 92 weeks postmenstrual age (PMA), with follow-up to 118 weeks PMA. STUDY DESIGN: This double-blinded study of 361 preterm infants randomized across three formula groups: (1) control, no supplementation; (2) algal-DHA (DHA from algal oil, ARA from fungal oil); and (3) fish-DHA (DHA from fish oil, ARA from fungal oil). Term infants breast-fed > or =4 months (n = 105) were a reference group. Outcomes included growth, tolerance, adverse events, and Bayley development scores. RESULTS: Weight of the algal-DHA group was significantly greater than the control group from 66 to 118 weeks PMA and the fish-DHA group at 118 weeks PMA but did not differ from term infants at 118 weeks PMA. The algal-DHA group was significantly longer than the control group at 48, 79, and 92 weeks PMA and the fish-DHA group at 57, 79, and 92 weeks PMA but did not differ from term infants from 79 to 118 weeks PMA. Supplemented groups had higher Bayley mental and psychomotor development scores at 118 weeks PMA than did the control group. Supplementation did not increase morbidity or adverse events. CONCLUSIONS: Feeding formulas with DHA and ARA from algal and fungal oils resulted in enhanced growth. Both supplemented formulas provided better developmental outcomes than unsupplemented formulas.
M Thomas Clandinin; John E Van Aerde; Kimberly L Merkel; Cheryl L Harris; Mary Alice Springer; James W Hansen; Deborah A Diersen-Schade
Related Documents :
7942577 - Effects of human milk or formula feeding on the growth, behavior, and protein status of...
17561927 - Growth of infants with ige-mediated cow's milk allergy fed different formulas in the co...
15870317 - Quantitative real-time pcr assays to identify and quantify fecal bifidobacterium specie...
8154907 - A randomised multicentre study of human milk versus formula and later development in pr...
14077037 - Leukemia, multiple myeloma, and aplastic anemia in american radiologists.
23916057 - Preoperative left ventricular internal dimension in end-diastole as earlier identificat...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  146     ISSN:  0022-3476     ISO Abbreviation:  J. Pediatr.     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-04-06     Completed Date:  2005-05-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  461-8     Citation Subset:  AIM; IM    
University of Alberta, Edmonton, Alberta, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arachidonic Acid / administration & dosage*
Docosahexaenoic Acids / administration & dosage*
Double-Blind Method
Follow-Up Studies
Infant Formula*
Infant, Newborn
Infant, Premature / growth & development*
Prospective Studies
Reg. No./Substance:
25167-62-8/Docosahexaenoic Acids; 506-32-1/Arachidonic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patterns of brain injury in term neonatal encephalopathy.
Next Document:  Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002.